4D Advisors LLC Invests $4.97 Million in DaVita Inc. $DVA

Key Points

• 4D Advisors LLC has acquired a new stake of 32,500 shares in DaVita Inc. valued at approximately $4.97 million, making it the company's 10th largest holding.
• DaVita reported a earnings per share of $2.95 for the last quarter, surpassing analysts' expectations of $2.70, while its revenue reached $3.38 billion, up 6.1% year-over-year.
• Currently, institutional investors own 90.12% of DaVita's stock, with several firms, including UMB Bank and National Pension Service, significantly increasing their stakes in the first quarter.

4D Advisors LLC purchased a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 32,500 shares of the company's stock, valued at approximately $4,972,000. DaVita makes up about 3.9% of 4D Advisors LLC's holdings, making the stock its 10th largest position.

Other hedge funds and other institutional investors have also bought and sold shares of the company. UMB Bank n.a. grew its position in DaVita by 65.5% during the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $29,000 after acquiring an additional 76 shares during the last quarter. National Pension Service grew its position in DaVita by 74.3% during the 1st quarter. National Pension Service now owns 197 shares of the company's stock worth $30,000 after acquiring an additional 84 shares during the last quarter. Copia Wealth Management bought a new stake in DaVita during the 4th quarter worth $30,000. Y.D. More Investments Ltd bought a new stake in DaVita during the 1st quarter worth $35,000. Finally, University of Texas Texas AM Investment Management Co. bought a new stake in DaVita during the 1st quarter worth $83,000. Institutional investors own 90.12% of the company's stock.

DaVita Price Performance

NYSE:DVA traded up $2.16 during trading hours on Friday, hitting $137.72. 659,996 shares of the company's stock traded hands, compared to its average volume of 686,564. The company has a quick ratio of 1.34, a current ratio of 1.39 and a debt-to-equity ratio of 23.18. The business's fifty day simple moving average is $139.40 and its two-hundred day simple moving average is $141.94. DaVita Inc. has a 52 week low of $126.07 and a 52 week high of $179.60. The firm has a market cap of $9.85 billion, a P/E ratio of 13.54, a P/E/G ratio of 0.97 and a beta of 1.13.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The firm had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.36 billion. During the same quarter in the previous year, the company posted $2.00 earnings per share. The company's revenue was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, research analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Insider Transactions at DaVita

In other DaVita news, insider James O. Hearty sold 2,351 shares of DaVita stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the sale, the insider owned 26,038 shares of the company's stock, valued at $3,905,700. The trade was a 8.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on DVA shares. Truist Financial set a $148.00 price objective on DaVita in a research report on Friday, August 8th. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a research report on Friday, August 22nd. Finally, Barclays reduced their price target on DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 7th. Three research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $164.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.